To navigate a challenging financing environment, founders must build loyalty with their existing shareholders. This means frequent communication about wins and setbacks, even with the earliest "friends and family" investors, to ensure they feel part of the journey and will participate in future financing rounds.

When giving challenging news, leaders cannot just "drop the bombshell and walk out." A successful approach requires three steps: 1) be clear and direct with the news, 2) provide the context and rationale behind it, and 3) stay to connect with the team, showing commitment and outlining next steps.

To manage investor expectations effectively, adopt a contrarian communication cadence. Only report good news (like a major deal) after it has officially closed, since many B2B deals fall through at the last minute. Conversely, report bad news as early as possible. This builds trust by preventing over-promising and demonstrating transparency when it matters most.

In a VC pitch, honestly admitting a knowledge gap can build more trust than attempting to bluff. It shows self-awareness and integrity, signaling to the investor that you'll be transparent when challenges arise. This candor is crucial for building the long-term founder-investor relationship.

Failing to send regular investor updates is interpreted negatively by VCs. They assume either the company is struggling, or the founder is ungrateful and disorganized. Consistent communication, even when brief, maintains trust and keeps investors primed to help.

When you have bad news to deliver—like a down-round valuation—don't soften the blow by revealing it in small increments. Take the hit all at once. 'Rip the darn band-aid off, tell everyone the bad news, they're adults, they can handle it, and get it done.'

Post-IPO, credibility is a biotech's most valuable asset. Leaders should "under-promise and over-perform" by avoiding specific quarterly guidance for clinical milestones. Instead, use broader windows like "first half of the year" to build in flexibility, as clinical trials rarely run on a perfect schedule.

When questioned about discrepancies where a 24-week dose underperformed on the primary endpoint but was strong on secondary ones, the CEO avoided direct comparisons. Instead, he framed the results as a 'totality of evidence' supporting the drug's profile, a key communication tactic for presenting complex or imperfect data positively to investors and regulators.

During crises like mergers, trust grows through predictability, not volume of information. Frequent, short check-ins—even to say there is no new information—are more effective than infrequent, dense downloads. This regular cadence creates a calming rhythm of clarity.